A strong suit of MIKAIA® is its wide portfolio of analysis apps for multiplexed immunofluorescence (mIF) / spatial proteomics. It can be used for both low-plex and high-plex panels and is compatbile with image formats...
How can the advanced AI analysis capabilities of MIKAIA® assist researchers and clinicians in analyzing their digital pathology and spatial biology data? This talk provides an overview of MIKAIA’s advanced...
In an increasingly complex world, users must process more and more information which makes information processing and decision-making all the more complex. Understanding cognitive load (i.e., the measurement of the...
This MIKAIA® app note demonstrates how to analyze a 47-plex spatial proteomics scan created with MACSima ™ (by Miltenyi Biotec), utilizing sequential immunofluorescence for the analysis: Instrument: MACSima™ by Miltenyi...
Researchers at the Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) have developed PEDRA: Platform for Ex-Vivo Drug Response Assays. Up to 100 compounds are tested in parallel on primary patient...
The Laboratory for Bio-Micro Devices at Brigham and Women’s Hospital () develops drug releasing implantable intratumoral microdevices (IMD) [1]. Using MIKAIA®, they want to examine in a quantitative fashion how...
The collection of robust and reliable medical data is essential for informed decision-making throughout the entire healthcare process and for health and wellbeing applications. Our approach to developing medical sensing...
CODEX, now called PhenoCycler, by Akoya Biosciences, along with other sequential immunofluorescence technologies (e.g., Lunaphore (Comet), Miltenyi Biotech (MACSima), Leica Microsystems (Cell DIVE), or other vendors)...
Tomorrow’s healthcare is increasingly data-driven. Collecting robust and reliable medical data is essential for making informed decisions at every step of the medical care process. Artificial intelligence (AI) plays a...